Gene Therapy
Durability, immunogenicity, and delivery are usually pitched as three separate engineering problems. They are one coupled system — a gain in any one is paid for in the others — and platform selection that ignores the coupling fails downstream.
Managing the Durability–Immunogenicity–Delivery Triad
- DOSSIERPlatform-selection analysis: AAV vs LNP vs emerging vehicles, with off-target and immunogenicity rigor and durability benchmarks.
- WORKBOOK21 sheets. 64 claims, each with a 6-way source-support verdict and a verbatim excerpt; 61 PubMed IDs live-resolved, 0 retracted.
- AUDITRelease-ready (90+). 61 citations live-resolved; one source error found and corrected.
- HYPOTHESES14 falsifiable, dated, on the coupled failure modes.
Exactly what's inside Managing the Durability–Immunogenicity–Delivery Triad.
The full research-report table of contents and every one of the 21 tables in the evidence workbook — the real structure of what you license, not a teaser.
- Report Scope & Evidence Integrity Statement
- 2026 Translational Signal Update (+ Evidence Refresh Addendum)
- Executive Summary
- Decision Snapshot
- Buyer Decision Cheat Sheet
- Source Quality Dashboard
- The Integrated-System Model
- Platform Comparison & Evidence Maturity Matrix
- Platform Deep-Dive Profiles
- Failure-Mode Convergence Map
- Key Findings & Quantitative Evidence
- Mechanistic Insights
- Safety, Immunogenicity & Genotoxicity Risks
- Durability Benchmarks & Tissue Gradient
- Off-Target & Specificity Assessment Rigor
- Manufacturing / CMC, Potency & Lot-to-Lot Immunogenicity
- Regulatory Pathway & Classification
- Company / Platform / Funding Landscape
- Commercial & Market Context
- Prioritized Non-Obvious Hypotheses (Flagship)
- Most Valuable Next Studies / Validation Strategies
- Validation & Falsification Gate Map
- Strategic Recommendations
- Final Judgment
- Expert Review & Validation Attestation
- Source Audit Summary
- References (Vancouver)
- Appendix: Methods, Glossary & Gate Compliance
Workbook Guide
An orientation to the workbook — its scope, how the claim counts reconcile, and the audit posture.
In this dossier: Companion to the dossier. Every customer-facing claim carries a verbatim source excerpt (Gate G3). Counts reconcile: 130 audited = 62 customer-facing + 68 excluded.
Claim Ledger
Every factual claim in the report, independently re-verified against its primary source, each carrying a support verdict and a recalibrated evidence grade.
In this dossier: 62 claims kept from 130 audited. main_result is extracted from the live source (replacing prior placeholders).
Evidence Table
The full registry of cited sources — PMIDs, NCTs and DOIs — with metadata, resolved live against the primary record.
In this dossier: Sources with live-verified metadata (NCBI eutils / ClinicalTrials.gov); journal/year populated from verification; PMCID duplicates removed.
Source Support Verdicts
The verbatim source excerpt behind each claim, with an independent verdict on whether the source actually supports it.
In this dossier: Every customer-facing verdict carries a verbatim quoted passage from the actual source + its location. No verdict assigned from title/claim-text matching.
Source Quality Summary
A reconciled view of source quality across the evidence base, with the grading rationale.
In this dossier: Counts reconcile across Claim Ledger, this summary, and Figure 9 grade distribution.
Platform Scorecard
Programs or modalities scored on the framework's axes — a structured, side-by-side comparison (expert, ordinal, non-evidentiary).
In this dossier: Decision axes per platform class (verified from Platform Comparison + 2026 refresh).
Triad Scorecard
Programs or modalities scored on the framework's axes — a structured, side-by-side comparison (expert, ordinal, non-evidentiary).
In this dossier: Controlling thesis: none of the three is individually solved; they are dynamically coupled.
Figure Source Map
The provenance of every figure — its underlying data and how it was produced.
In this dossier: 18 figures: engine (deterministic/generative), sources, caption, status. Generative carry generation prompts.
Figure Attempt Ledger
The provenance of every figure — its underlying data and how it was produced.
In this dossier: Build status for every figure. 0 PENDING.
Hypotheses Ledger
The forward-looking, falsifiable hypotheses — each with a predicted readout and an explicit disconfirming test.
In this dossier: Each is non-obvious, forward (2026-2028), falsifiable, and source-grounded. Premises trace to verified citations.
Next Studies
The highest-leverage experiments to run next, prioritized — a ready-made research agenda.
In this dossier: 10 falsifiable studies linked to hypotheses and verified evidence gaps.
Validation Gates
A structured table within the evidence workbook.
In this dossier: Binary gates with PASS/FAIL criteria. All OPEN as of the evidence window (June 2026).
OffTarget-Immuno Assays
A structured table within the evidence workbook.
In this dossier: Methods, sensitivity/LoD and context; incorporates 2026 methods. Off-target claims must specify method + LoD.
CMC Risk Matrix
A structured map across this dimension of the analysis.
In this dossier: Risks x severity x likelihood x mitigation.
Regulatory Tracker
Regulatory designations and pathways relevant to each program — noting that a designation is never an approval.
In this dossier: Guidance/standards with provenance. No defined pathway asserted beyond verified guidance.
Company-Funding Tracker
A structured tracker of the programs, signals and evidence in this dimension of the analysis.
In this dossier: Programs with provenance qualifiers. Approvals/registry distinguished from company-reported/aspirational.
Trial-Registry Tracker
A structured tracker of the programs, signals and evidence in this dimension of the analysis.
In this dossier: Every NCT opened and confirmed via ClinicalTrials.gov API v2. COR-001: NCT06128629 is Intellia ATTR (not Beam GSDIa); Beam GSDIa = NCT06735755.
2026 Update Sources
A structured table within the evidence workbook.
In this dossier: NEW forward-search sources beyond the original citation set, tagged confirm/update/supersede. All resolve; 0 retracted.
Expert Review
A structured table within the evidence workbook.
In this dossier: Point-in-time; no future-update obligation.
Gate Compliance Ledger
A structured table within the evidence workbook.
In this dossier: Binary audit-gate compliance with proof pointers. The dossier is not deliverable without this.
Excluded Claims
Every claim we considered and removed, with the reason — showing the work, including what didn't make the cut.
In this dossier: 68 excluded from the 130-claim audit (59 off-topic + 9 structural). Moved out of customer-facing set.
Click any table to see what it is.
Different buyers live in different tabs.
Click a buyer to see exactly what they get.
Every claim resolves to a primary source.
This dossier ships with its independent diligence audit. Evidence is labelled Established / Inferred / Hypothesis. A surrogate is never equated with outcome; a designation is never an approval.
Zemi Research publishes independent, pre-packaged research reports delivered as digital downloads (PDF + spreadsheet). These are information products — not medical, clinical, investment, legal, or professional advice; not a consulting, advisory, or regulated service; and they create no professional-client relationship. Provided for general informational use by industry professionals.